This was a very successful meeting, which brought together leading experts in the treatment and research of IPF and provided a forum for the discussion and sharing of new developments, committee guidance and clinical experience. The 2011 guidelines from the ATS/ERS/JRS/ALAT joint committee \[[@B1]\] provide a very good background for physicians managing patients with IPF, giving great detail in terms of the approach to diagnosing patients. Newly refined criteria were published, which gave a central role to the usefulness and implementation of high-resolution computed tomography scanning in the diagnostic algorithm.

During the meeting, there was much discussion around the daily challenges faced by physicians who have patients with IPF, which remain even after the publication of the updated guidelines. Although considered highly useful by the majority of attendees, it was generally felt that an update to the 2011 publication would be useful, to fully incorporate research outcomes that weren't included in the existing analysis, such as the complete dataset regarding the efficacy of pirfenidone and the closing of studies of warfarin treatment, along with safety data regarding the N-acetylcysteine, azathioprine and prednisone combination therapy. It is now possible to reassess the treatment recommendations of these agents. In addition, the presentations and discussions held at the meeting identified specific issues within the diagnosis recommendations. By addressing these points, we will have an even stronger platform on which to base our patient management approaches, and will be able to provide a more confident diagnosis along with the most effective treatment options available to date. This is a very exciting time in IPF research, and we, as physicians, are driving the progress and trying to improve the outlook for patients with this difficult-to-treat disease. A key take-home message from this meeting is that each patient should be viewed as an individual case when considering the diagnostic and disease management approaches. As previously mentioned, with continuing support and enthusiasm from its attendees, the AIR Meeting should become an annual event in the calendar for respiratory physicians and researchers dedicated to advancing the treatment and management of patients with IPF.
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